In an “urgent medical device correction,” the company urges clinicians to remind patients to monitor their glucose levels during takeoffs and landings.

Truist raised the firm’s price target on Medtronic (MDT) to $93 from $89 and keeps a Hold rating on the shares after its Q3 earnings beat.

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

Goldman Sachs analyst David Roman raised the firm’s price target on Medtronic (MDT) to $85 from $83 and keeps a Sell rating on the shares. The ...

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

From leadership updates to FDA clearances, here are five key updates from spine and orthopedic medtech companies since Feb. 12.

Medtronic beat Wall Street estimates for third-quarter profit on Tuesday, partly helped by demand for its diabetes devices, ...

Shares of Medtronic are benefiting from an improved ... And in the highly competitive diabetes care segment, the new MiniMed 780G insulin pump system employs AI algorithms to predict and ...

Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation ...

Medtronic (NYSE:MDT) issued an urgent field safety notice in Europe related to multiple versions of its MiniMed insulin pump ...

While this is a fun, satisfying sight to behold, it's unfortunately temporary. Known as a muscle pump, this type of instant muscle growth occurs for a reason. But does it actually have any ...